

Gilead Unveils New Technical Development Center: A State-of-the-Art Biologics Innovation Hub

Gilead Sciences has broken ground on its new Pharmaceutical Development & Manufacturing Technical Development Center at the company's Foster City headquarters. The building is a cornerstone of the company's \$32 billion U.S. investment strategy projected to generate more than \$43 billion in economic value. A state-of-the-art, AI-enabled hub, the five-story, 180,000-square-foot facility will bring together approximately 300 colleagues to advance next-generation biologics and strengthen America's biomanufacturing leadership. The Center reflects Gilead's commitment to innovation, sustainability, patients and communities.

The New Technical Development Center: By the Numbers



**5 stories |
181,000 sq ft**

**300 colleagues |
190 lab users**

**Bespoke biologics
& single-use pilot lab**

**ILFI Zero Carbon |
LEED Gold**

**Digital Twin & Unified
Namespace Architecture**

Q3 2027 Targeted Opening

PROJECT HIGHLIGHTS

Biologics Innovation & Strategy

- The new Center is a centerpiece of Gilead's Biologics Master Plan to co-locate R&D and clinical manufacturing for speed and agility
- Designed to support state-of-the-art technical development capabilities for biologics in Foster City, while maintaining seamless campus integration
- Parallel to an investment in cutting-edge biologics clinical manufacturing in Foster City

Cutting-Edge Technical Capabilities

- Digital Twin & BIM/Enscape Modeling for streamlined construction and commissioning
- All-electric design with advanced mechanical and electrical systems
- Integrated Supervisory Control and Data Acquisition (SCADA), Manufacturing Execution System (MES) and AWS Unified Namespace (UNS) for seamless tech transfer and data visibility

SUSTAINABILITY LEADERSHIP

- No fossil fuel combustion
- **100%** renewable electricity sourcing
- Targeted elimination of Red List chemicals in building materials
- **97%** construction waste diverted from landfill
- Low-water, native landscaping
- Embodied Carbon Target **<500 kg CO2e/m2**

“

The new Technical Development Center represents Gilead's bold commitment to redefining biologics development, accelerating speed-to-patient with sustainability and digital integration at its core.

– Stacey Ma, Executive Vice President, Pharmaceutical Development & Manufacturing

”